THE CLINICAL-STAGE DRUG BTZ-043 ACCUMULATES IN MURINE TUBERCULOSIS LESIONS AND EFFICIENTLY ACTS AGAINST MYCOBACTERIUM TUBERCULOSIS

The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis

Abstract The development of granulomas with central necrosis harboring Mycobacterium tuberculosis (Mtb) is the hallmark of human tuberculosis (TB).New anti-TB therapies need to effectively penetrate the cellular and necrotic compartments of these lesions and reach sufficient concentrations to eliminate Mtb.BTZ-043 is a novel antibiotic showing good

read more